Drugs / Synovian
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT07267793 | Jul 2025 → Feb 2026 overdue | osteoarthritis, knee | DALIM TISSEN Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06307847 Comparator | Apr 2021 → Oct 2022 | osteoarthritis, hand | Shin Poong Pharmaceutical Co. Ltd. | Completed | Met primary |
| Phase 3 | NCT03561779 Comparator | Feb 2018 → Jun 2019 | osteoarthritis, knee | Yooyoung Pharmaceutical Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Synovian | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03561779 ↗ |
| Modality | Other / unclassified | “1,4-butanediol diglycidyl ether cross-linked hyaluronate (Synovian)” PMID 34736768 ↗ Nov 2021 |
| Route | Other | “the efficacy and safety of the intra-articular injection treatment for osteoarthritis of the knee joint” PMID 34736768 ↗ Nov 2021 |